Chimeric antibody remicade

Anti-TNF antibodies human-mouse chimeric antibody (infliximab or Remicade). A trial in the treatment of Crohn s disease noted infusion reactions, transient increased of anti-dsDNA antibodies, and serum sickness-like delayed hypersensitivity with retreatment. Induction of human-antichimeric-antibodies was suggested as the cause of some of the infusion reactions [31]. 

Infliximab (Remicade) is a chimeric monoclonal antibody directed against TNF-a. Recently, its indications have been expanded to include psoriatic arthritis and treatment of adults with chronic severe plaque psoriasis. An advantage over other systemic psoriasis treatments is that infliximab does not adversely affect blood counts, hepatic enzyme levels, or kidney function. The recommended dose is 5 mg/kg as an IV infusion at weeks 0, 2, and 6, then every 8 weeks thereafter. For psoriatic arthritis, it may be used with or without methotrexate. Adverse effects include headaches, fever, chills, fatigue, diarrhea, pharyngitis, upper respiratory and urinary tract infec-... 

Infliximab (Remicade) is a chimeric IgGi monoclonal antibody composed of human constant and murine variable regions. 

Infliximab (Remicade) is a mouse-human chimeric monoclonal antibody that binds to soluble and membrane-bound TNF-a and inhibits binding with its receptors. Infliximab is a complement-fixing antibody that induces complement-dependent and cell-mediated lysis when bound to cell-surface-bound TNF-a. It also induces proinflammatory cytokines, such as IL-1 and IL-6, and enhances leukocyte migration. Infliximab is FDA approved for the treatment of Crohn s disease and rheumatoid arthritis, but it is also in phase trials for the treatment of psoriasis. 

Chimeric monoclonal antibody (engineered protein) A. Remicade... 

Infliximab Infliximab (remicade) is a chimeric anti-TNF-a monoclonal antibody containing a human constant region and a murine variable region. It binds with high affinity to TNF-a and prevents the cytokine from binding to its receptors. 

Infliximab (Remicade) is a chimeric monoclonal antibody against tumor necrosis factor (TNF)-alpha that has shown efficacy in Crohn s disease and rheumatoid arthritis with a disease-modifying activity and rapid onset of action [237]. It is administered intravenously, generally in a schedule with initial infusions at 0, 2, and 6 weeks, followed by administration once every 8 weeks. Infliximab is effective in the treatment of patients with moderately to severely active Crohn s disease with an inadequate response to other treatment options or those with fistulizing disease. In combination with methotrexate, infliximab reduced signs and symptoms and... 

---